Clinical Trials for Kidney Cancer

A Phase 1/1b Open-label, Multi-center Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Enrolling adults with locally advanced or metastatic clear cell RCC (ECOG 0–1) previously treated with standard systemic therapy—dose escalation requires ≥2 prior regimens including immunotherapy and a targeted therapy, and expansion cohorts require prior exposure to both a PD-1/L1 inhibitor and a VEGF TKI. Participants receive oral BMS-986506 monotherapy (first-in-human small molecule; target/mechanism not publicly specified) with primary focus on safety/DLTs and secondary pharmacokinetics and preliminary RECIST activity.

ClinicalTrials.gov ID: NCT07195682

An Open-Label, First-in-Human, Phase 1/2 Dose Escalation and Expansion Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: For adults with locally advanced or metastatic unresectable clear cell renal cell carcinoma who have progressed on or declined standard therapies (ECOG 0–1, RECIST-measurable disease, eGFR ≥60, with available FFPE tumor tissue), this single-arm study evaluates escalating oral NEO-811 monotherapy given in 21-day cycles. NEO-811 is an investigational agent with an undisclosed molecular target/mechanism, assessed primarily for safety/tolerability and dose selection with preliminary RECIST activity.

ClinicalTrials.gov ID: NCT07300241

A Randomized Phase I/II Study of Talazoparib or Temozolomide in Combination With Onivyde in Children With Recurrent Solid Malignancies and Ewing Sarcoma

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Enrolls children/AYA age >12 months to <30 years with recurrent/refractory non-CNS solid tumors (dose-finding/expansion, including an HRR-altered cohort) and randomizes patients with first-relapse, EWSR1-rearranged Ewing sarcoma to compare efficacy. Treatment is nanoliposomal irinotecan (Onivyde; topoisomerase I–mediated DNA damage) on days 1 and 8 of 21-day cycles combined with either talazoparib (PARP1/2 inhibitor with PARP-trapping) or temozolomide (oral DNA-alkylating agent).

ClinicalTrials.gov ID: NCT04901702

A Phase 1, Open-Label, Multicenter Study of INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Enrolling adults with ECOG 0–1 and advanced CD70-expressing malignancies needing additional therapy: ccRCC after ≥1 prior line including ICI+TKI, DLBCL/high-grade B-cell lymphoma after ≥2 prior lines including immunochemotherapy and salvage, peripheral T-cell lymphoma after ≥1 systemic therapy, or CTCL (mycosis fungoides/Sézary) stage IIB+ with B0/B1 blood involvement after ≥1 systemic therapy. Participants receive INCA036873 monotherapy, an investigational CD70×CD3 bispecific T-cell engager intended to redirect T cells to kill CD70-positive tumor cells.

ClinicalTrials.gov ID: NCT07195916

Selective Antigen Specific dTβRII-expressing T Cells and B7-H3 CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABRE)

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Eligible patients are children, adolescents, and young adults (age 1 to <24 years; >10 kg) with relapsed/refractory rhabdomyosarcoma, Ewing sarcoma, neuroblastoma, or Wilms tumor with measurable/evaluable disease after standard therapies and no known CNS involvement. After fludarabine/cyclophosphamide lymphodepletion, participants receive a single infusion of an autologous 1:1 cellular product combining B7-H3–targeted CAR T cells with PRAME antigen–specific T cells engineered with a dominant-negative TGF-β receptor II (dTβRII) to resist TGF-β–mediated immunosuppression.

ClinicalTrials.gov ID: NCT07172958

A First-In-Human Phase 1/2 Open-Label Study of Intravenous ST-067, Subcutaneous ST-067 with or Without Obinutuzumab Pre-Treatment, and ST-067 in Combination with Pembrolizumab in Subjects with Advanced Solid Malignancies

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: This trial involves adult patients with advanced or metastatic solid tumors such as melanoma and non-small cell lung cancer who have relapsed after standard treatments, testing the investigational agent ST-067 alone or with pembrolizumab and obinutuzumab to enhance immune response against tumor cells.

ClinicalTrials.gov ID: NCT04787042

A Phase 1 Study With ABBV-CLS-484 Alone and in Combination in Subjects With Locally Advanced or Metastatic Tumors

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with advanced or metastatic solid tumors who have progressed after or are ineligible for standard therapies—including specific expansion cohorts for relapsed/refractory head and neck, non-small cell lung, clear cell renal cell carcinoma, or MSI-H tumors—are eligible to receive ABBV-CLS-484 (an oral PTPN2/PTPN1 inhibitor targeting immune evasion) as monotherapy or combined with a PD-1 inhibitor or VEGFR tyrosine kinase inhibitor.

ClinicalTrials.gov ID: NCT04777994

A Phase Ia/Ib, Open Label, Multicenter, Dose-escalation Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Checkpoint Inhibitor in Patients With Locally Advanced or Metastatic Solid Tumors

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with incurable, locally advanced or metastatic solid tumors (e.g., NSCLC, HNSCC, melanoma, TNBC, GI, cervical, CRC, urothelial, clear cell RCC, HCC) receive RO7502175, an afucosylated anti-CCR8 IgG1 designed to deplete intratumoral Tregs via enhanced ADCC, as monotherapy or combined with PD-(L)1 inhibitors (atezolizumab or pembrolizumab). Eligible patients have ECOG 0–1, measurable disease, and no active infections, autoimmune disease, or untreated CNS metastases.

ClinicalTrials.gov ID: NCT05581004